The clinical implications of the difference between castration, gonadotrophin releasing-hormone (GnRH) antagonists and agonist treatment on the morphology and expression of GnRH receptors in the rat ventral prostate

BJU International

Volumn 91, Issue 3, 2003, Pages 227-233

  Tieva, A ^a   Bergh, A ^a   Damber, J E ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Agonist; Antagonist; Competitive RT PCR; GnRH receptors; Pituitary; Prostate; Rat

Indexed keywords

CETRORELIX; CYCLOPHILIN; FOLLITROPIN; FOLLITROPIN RECEPTOR; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; GOSERELIN; KI 67 ANTIGEN; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; TESTOSTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CASTRATION; CELL PROLIFERATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG MECHANISM; HOUSEKEEPING GENE; HYPOPHYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; MALE; NONHUMAN; ORCHIECTOMY; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROSTATE; PROSTATE EPITHELIUM; PROSTATE VENTRAL LOBE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STEREOLOGY; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE;

ANIMALS; GONADOTROPIN-RELEASING HORMONE; IMMUNOHISTOCHEMISTRY; MALE; ORCHIECTOMY; PITUITARY GLAND; PROSTATE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LHRH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0037328865     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.03054.x     Document Type: Article

References (35)

1. Conn PM, Crowley FW. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994; 45: 391-405
2. Marian J, Cooper RL, Conn PM. Regulation of the rat pituitary gonadotropin-releasing hormone receptor. Mol Pharmocol 1981; 19: 399-405
3. Clayton NR, Catt JK. Gonadotropin-releasing hormone receptors. Characterisation, physiological regulation, and relationship to reproductive function. Endocr Rev 1981; 2: 186-209
4. Belchetz EP. Gonadotrophin regulation and clinical applications of GnRH. Clin Endocrinol Metab 1983; 12: 619-40
5. Bare RL, Torti FM. Endocrine therapy of prostate cancer. Cancer Treat Res 1998; 94: 69-87
6. Tomera K, Gleason D, Gittelman M et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin, initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001; 165: 1585-9
7. Neill JD, Duck WL, Sellers JC, Musgrove LC. A Gonadotropin-releasing Hormone (GnRH) receptor specific for GnRH II in primates. Biochem Biophys Res Commun 2001; 282: 1012-8
8. Millar R, Lowe S, Conklin D et al. A novel mammalian receptor for the evolutionary conserved type II GnRH. Proc Natl Acad Sci USA 2001; 98: 9636-41
9. Dondi D, Limonta P, Moretti MR, Marelli MM, Garattini E, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 148: Evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994; 54: 4091-5
10. Limonta P, Dondi D, Moretti MR, Maggi R, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992; 75: 207-12
11. Yano T, Pinski J, Radulovic S, Schally AV. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1994; 91: 1701-5
12. Qayum A, Gullick W, Clayton CR, Sikora K, Waxman J. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 1990; 62: 96-9
13. Qayum A, Gullick WJ, Mellon K et al. The partial purification and characterization of GnRH-like activity from prostatic biopsy specimens and prostatic cancer cell lines. J Steroid Biochem Mol Biol 1990; 37: 899-902
14. Redding WT, Schally VA, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs TJ. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Cancer Res 1992; 52: 2538-44
15. Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M, Motta M. The luteinizing hormone-releasing hormone receptor in human prostate cancer cells. messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 1999; 140: 5250-6
16. Szende B, Takács J, Mezô I, Szegedi Z, Kéri G. Binding of a radiolabeled tumor selective GnRH analog to PC-3 human prostate cancer cells and the induction of apoptosis. Endocrine 1994; 2: 645-9
17. Fekete M, Redding TW, Comaru-Schally AM et al. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate 1989; 14: 191-208
18. Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000; 163: 623-9
19. Tieva A, Stattin P, Wikstrom P, Bergh A, Damber JE. Gonadotropin-releasing hormone receptor expression in the human prostate. Prostate 2001; 47: 276-84
20. Srkalovic G, Bokser L, Radulovic S, Korkut E, Schally VA. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75. Endocrinology 1990; 127: 3052-60
21. Tieva A, Wilkstrom P, Olofsson JI, Bergh A, Damber JE. Expression of gonadotropin-releasing hormone receptor mRNA in the rat ventral prostate and dunning R3327 PAP adenocarcinoma before and after castration. Prostate 1999; 39: 101-7
22. Pinski J, Reile H, Halmos G, Groot K, Schally VA. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer 1994; 59: 51-5
23. Damber JE, Janson PO. The effects of LH, adrenaline and noradrenaline on testicular blood flow and plasma testosterone concentrations in anaesthetized rats. Acta Endocrinal (Copenh) 1978; 88: 390-6
24. Moumni M, Kottler M-L, Counis R. Nucleotide sequnce analysis of mRNAs predicts that rat pituitary and gonadal gonadotropin-releasing hormone receptor proteins have identical primary structure. Biochem Biophys Res Commun 1994; 200: 1359-66
25. Danielson EP, Forss-Petter S, Brow AM et al. p 1B15. A eDNA clone of the rat mRNA encoding cyclophilin. DNA 1988; 7: 261-7
26. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-5
27. Westin P, Bergh A, Damber JE. Castration rapidly results in a major reduction in epithelial cell numbers in the rat prostate, but not in the highly differentiated Dunning R3327 prostatic adenocarcinoma. Prostate 1993; 22: 65-74
28. Emons G, Schally VA. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Human Reprod Update 1994; 9: 1364-79
29. Kovacs M, Schally AV, Csernus B, Rekasi Z. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH. Proc Natl Acad Sci USA 2001; 98: 1829-34
30. Jungwirth A, Schally VA, Nagy A et al. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol 1997; 10: 877-84
31. Tomera K, Gleason D, Gittelman M et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin. initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001; 165: 1585-9
32. Kaiser UB, Jakubowiak A, Steinberger A, Chin WW. Regulation of rat pituitary gonadotropin-releasing hormone receptor mRNA levels in viva and in vitro. Endocrinology 1993; 133: 931-4
33. Azad N, Uddin S, Paglia LN et al. Luteinizing hormone-releasing hormone (LHRH) in rat prostate. Characterization of LHRH peptide, messenger ribonucleic acid expression, and molecular processing of LHRH in intact and castrated male rats. Endocrinology 1993; 133: 1252-7
34. Yano T, Pinski J, Szepeshazi K, Milanovic RS, Groot K, Schally VA. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model. Prostate 1992; 20: 297-310
35. Lamharzi N, Halmos G, Jungwirth A, Schally AV. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol 1998; 13: 429-35